Drugs / Autologous Tcm cells immunotherapy
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03432156 | Apr 2018 → Dec 2019 | non-small cell lung carcinoma | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03389438 | Feb 2018 → Feb 2021 | urinary bladder neoplasm | Beijing Huanxing Cancer Hospital | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Tcm cells immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03432156 ↗ |
| Modality | Cell therapy | “Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro” NCT03389438 ↗ |